Nestlé to fully own Aimmune Therapeutics through $2bn deal
Nestlé will take full ownership of Aimmune Therapeutics, the developer of FDA approved peanut allergy drug Palforzia, by acquiring the remaining stake of 74.4% in ... Read More
First patients being treated with Aimmune’s PALFORZIA peanut allergy drug
Aimmune Therapeutics said that the first patients in the US are being treated with the recently FDA approved peanut allergy drug PALFORZIA . The California-based ... Read More